Net Zero Strategies in the Pharmaceutical Sector – Thematic Intelligence

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Net Zero Strategies in the Pharmaceutical Sector Thematic Overview

Net zero means cutting greenhouse gas emissions (GHG) to as close to zero as possible. Firms that achieve net zero emissions are called “carbon neutral”. Companies are under pressure to cut emissions as countries aim to achieve their climate commitments. Emissions are offset by supporting projects that reduce emissions or remove greenhouse gases from the atmosphere. The CHG protocol classifies direct and indirect emissions into Scope 1, 2 & 3. Scope 1 and 2 emissions are generated by business operations. Scope 3 encompasses emissions up and down the value chain.

Most pharmaceutical companies have started reducing Scope 1 and 2 emissions. This has typically been achieved by using electricity from renewable sources, including increased amounts of on-site power generation such as solar panels. Most companies have targets for 100% renewable energy use and all-electric vehicle fleets. On average, 90% of a pharmaceutical company’s emissions are Scope 3 emissions. Companies can only change their Scope 3 emissions by changing or influencing suppliers or by creating products that generate less emissions when used.

Major pharmaceutical companies including Gilead, Pfizer, Novartis, AstraZeneca, and GSK have set short-term targets for minimizing emissions. Leading pharmaceutical companies are also joining industry groups such as Energize and Activate that aim to help suppliers reduce their emissions.

The “Net Zero Strategies in The Pharmaceutical Sector” thematic intelligence report gives you an in-depth insight into the net zero targets and performance of 18 leading pharmaceutical companies. The report elucidates the importance of a net zero strategy in the pharmaceutical sector along with the progress made by the leading companies to achieve the emission target. These detailed analyses are critical in developing effective business plans to gain a competitive edge.

A Stylized Net Zero Strategy
A Stylized Net Zero Strategy
Buy the Full Report to Know More About the Net Zero Strategies in the Pharmaceutical Sector Market

Download a Free Report Sample

Leading Companies ·       AstraZeneca

·       Pfizer

·       Amgen

·       Takeda

Enquire & Decide

Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Pharmaceutical Sector - Scope 1, 2, and 3 Emissions Strategies

Pharmaceutical companies are focused on reducing emissions in stores, distribution centers, warehouses, and offices. Some of the key strategies used for curbing Scope 1 and 2 emissions by pharma industry players are LED retrofitting and electrifying vehicle fleets. Furthermore, the use of efficient HVAC systems as well as refrigeration and cooling systems by pharmaceutical companies has further propelled the minimization of Scope 1 and 2 emissions. To tackle scope 3 emissions, pharma companies are pressurizing suppliers to set emission reduction targets. For instance, 95% of suppliers to AstraZeneca will have science-based targets by 2025. Pharma companies are also using cross-industry initiatives such as Activate and Energize for decarbonizing supply chains.

Activate: AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, and Sanofi launched Activate, at the COP27 climate conference in 2022. The initiative aims to help suppliers by supporting green chemistry solutions and making financing available for decarbonization projects.

Buy the Full Report for More Insights on Emission Strategies in the Pharmaceutical Sector

Download a Free Report Sample

Pharmaceutical Sector - Net Zero Strategies of Leading Companies

A few pharmaceutical companies evaluated in this report are AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Gilead Sciences, and GSK among others. Of these, AstraZeneca, Pfizer, Amgen, and Takeda have made notable progress with the most ambitious net-zero strategies.

Pfizer: The company is conducting life cycle assessments (LCAs) for drugs, vaccines, and devices for reducing Scope 3 emissions over the long term. It is part of industry groups like Energize and Activate, which aim to help suppliers decarbonize while adopting some of the most ambitious targets for reducing value chain emissions.

Buy the Full Report for More Company-Wise Net Zero Strategy Analysis in the Pharmaceutical Sector Industry

Download a Free Report Sample

Scope

  • This thematic report provides an overview of the greenhouse gas emissions reduction targets, data, and strategies of 18 leading pharmaceutical companies.

Key Highlights

All major pharmaceutical companies have committed to reducing their greenhouse gas emissions. To achieve these goals they are adapting their operations and products and are increasingly engaging with suppliers to reduce emissions across their supply chain.

Reasons to Buy

The thematic research report will help you:

  • Understand the environmental footprint of pharmaceutical operations.
  • Enhance the company’s reputation by demonstrating a commitment to environmental responsibility.
  • Gain insights into current environmental regulations.

Table of Contents

Executive Summary

Why Pharmaceutical Companies Need a Net Zero Strategy

Emissions Targets and Performance

Scope 1 and 2 Emissions Strategies

Scope 3 Emissions Strategies

Glossary

Further Reading

Our Thematic Research Methodology

Contact US

Frequently asked questions

Net Zero Strategies in the Pharmaceutical Sector – Thematic Intelligence thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Net Zero Strategies in the Pharmaceutical Sector – Thematic Intelligence was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Business and Consumer Services
New
Slovakia PESTLE Insights: A Macroeconomic Outlook Report
$500 | November 2026
Business and Consumer Services
New
United Arab Emirates (UAE) PESTLE Insights: A Macroeconomic Outlook Report
$500 | November 2026
Business and Consumer Services
New
United Kingdom (UK) PESTLE Insights: A Macroeconomic Outlook Report
$500 | October 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Net Zero Strategies in the Pharmaceutical Sector – Thematic Intelligence in real time.

  • Access a live Net Zero Strategies in the Pharmaceutical Sector – Thematic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.